RU2000102364A - VECTOR FOR EXPRESSION OF A HETEROLOGICAL PROTEIN AND METHODS OF EXTRASION OF A RECOMBINANT PROTEIN AND CLEANING OF THE IDENTIFIED RECOMBINANT INSULIN - Google Patents

VECTOR FOR EXPRESSION OF A HETEROLOGICAL PROTEIN AND METHODS OF EXTRASION OF A RECOMBINANT PROTEIN AND CLEANING OF THE IDENTIFIED RECOMBINANT INSULIN

Info

Publication number
RU2000102364A
RU2000102364A RU2000102364/13A RU2000102364A RU2000102364A RU 2000102364 A RU2000102364 A RU 2000102364A RU 2000102364/13 A RU2000102364/13 A RU 2000102364/13A RU 2000102364 A RU2000102364 A RU 2000102364A RU 2000102364 A RU2000102364 A RU 2000102364A
Authority
RU
Russia
Prior art keywords
cell membrane
sequence encoding
vector
protein
recombinant
Prior art date
Application number
RU2000102364/13A
Other languages
Russian (ru)
Other versions
RU2222598C2 (en
Inventor
Спартаку АСТОЛФИ-ФИЛЬЮ
ЛИМА Биатрис Долабела ДИ
Джозеф Эрнст ТИМАНН
СОЗА Элоиза Рибейру Тунес ДИ
Люсиано ВИЛЕЛА
Original Assignee
Универсидади Ди Бразилиа
Биобрас С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/886,967 external-priority patent/US6068993A/en
Application filed by Универсидади Ди Бразилиа, Биобрас С.А. filed Critical Универсидади Ди Бразилиа
Publication of RU2000102364A publication Critical patent/RU2000102364A/en
Application granted granted Critical
Publication of RU2222598C2 publication Critical patent/RU2222598C2/en

Links

Claims (15)

1. Вектор, включающий молекулу нуклеиновой кислоты, для экспрессии, по крайней мере, одного гетерологичного белка, при том, что упомянутый вектор включает следующие функционально соединенные участки в направлении 5' --> 3':
(i) последовательность, кодирующая сайт начала репликации;
(ii) последовательность, кодирующая промотор;
(iii) последовательность, кодирующая инициирующий сегмент;
(iv) последовательность, кодирующая, по крайней мере, один рестрикционный сайт, предназначенный для встраивания гетерологичной ДНК, кодирующей, по крайней мере, один гетерологичный белок и
(v) последовательность, кодирующая сайт терминации транскрипции.1. A vector, including a nucleic acid molecule, for the expression of at least one heterologous protein, while the said vector includes the following functionally connected sections in the direction 5 '->3':
(i) a sequence encoding a replication start site;
(ii) a sequence encoding a promoter;
(iii) a sequence encoding a trigger segment;
(iv) a sequence encoding at least one restriction site for embedding a heterologous DNA encoding at least one heterologous protein; and
(v) a sequence encoding a transcription termination site. 2. Вектор по п. 1, отличающийся тем, что молекулой нуклеиновой кислоты является ДНК. 2. The vector according to claim 1, characterized in that the nucleic acid molecule is DNA. 3. Вектор по п. 1, отличающийся тем, что инициирующий сегмент включает сайт инициации трансляции. 3. The vector according to claim 1, characterized in that the initiating segment includes a translation initiation site. 4. Вектор по п. 1, отличающийся тем, что после (i) и перед (ii) находится последовательность, кодирующая селективный маркер. 4. The vector according to claim 1, characterized in that after (i) and before (ii) there is a sequence encoding a selective marker. 5. Вектор по п. 1, отличающийся тем, что он является плазмидой для экспрессирования в грамм-отрицательной бактерии. 5. The vector according to claim 1, characterized in that it is a plasmid for expression in a gram-negative bacterium. 6. Вектор, определенный в п. 5, отличающийся тем, что грамм-отрицательной бактерией является кишечная палочка Е. coli, сайт начала репликации происходит из плазмиды pUC8, инициирующий сегмент является сайтом инициации трансляции, включающим синтетический участок Шайна-Дальгарно, происходящий из гена 10 фага Т7, имеется последовательность, кодирующая селективный маркер, расположенная между (i) и (ii), включающая последовательность, кодирующую резистентность к тетрациклину, промотором является промотор РL и сайтом терминации транскрипции является Rho-независимый.6. The vector as defined in claim 5, characterized in that the E. coli E. coli is a gram-negative bacterium, the origin of replication originates from the plasmid pUC8, the initiating segment is the translation initiation site, including the Shine-Dalgarno synthetic region, originating from the gene 10 of phage T7, there is a sequence encoding a selectable marker located between (i) and (ii), including a sequence encoding a tetracycline resistance, the promoter is the R L promoter and the transcription termination site is Rho-independent. 7. Вектор по п. 1, отличающийся тем, что по крайней мере, один рестрикционный сайт кодирует множественные рестрикционные сайты. 7. The vector according to claim 1, characterized in that at least one restriction site encodes multiple restriction sites. 8. Вектор по п. 7, отличающийся тем, что множественные рестрикционные сайты представляют собой NcoI, EcoRI, StuI, PstI, BamHI и BspEI. 8. The vector according to claim 7, characterized in that the multiple restriction sites are NcoI, EcoRI, StuI, PstI, BamHI and BspEI. 9. Вектор по п. 1, отличающийся тем, что гетерологичным белком является проинсулин. 9. The vector according to claim 1, characterized in that the heterologous protein is proinsulin. 10. Способ экстрагирования рекомбинантного белка изнутри клеток рекомбинантных грамм-отрицательных бактерий, имеющих клеточную мембрану, без лизирования бактерий, включающий следующие этапы:
(a) пермеабилизация клеточной мембраны путем обработки бактерий детергентом при соблюдении условий, достаточных для разделения нативных клеточных белков от клеточной мембраны без разделения рекомбинантного белка от клеточной мембраны;
(b) солюбилизация рекомбинантного белка и клеточной мембраны;
(c) отделение рекомбинантного белка от клеточной мембраны.10. A method of extracting a recombinant protein from within cells of recombinant gram-negative bacteria having a cell membrane without lysing bacteria, comprising the following steps:
(a) permeabilization of the cell membrane by treating the bacteria with a detergent under sufficient conditions to separate native cell proteins from the cell membrane without separating the recombinant protein from the cell membrane;
(b) solubilization of the recombinant protein and cell membrane;
(c) separating the recombinant protein from the cell membrane. 11. Способ по п. 10, отличающийся тем, что детергентом, используемым на этапе (а), является Тритон Х-100. 11. The method according to p. 10, characterized in that the detergent used in step (a) is Triton X-100. 12. Способ по п. 10, отличающийся тем, что на этапе (а) условия, являющиеся достаточными для отделения нативных клеточных белков от клеточной мембраны, представлены центрифугированием, и полученный в результате осадок содержит рекомбинантный белок с клеточной мембраной. 12. The method according to p. 10, characterized in that at step (a) the conditions that are sufficient to separate the native cell proteins from the cell membrane are represented by centrifugation, and the resulting pellet contains a recombinant protein with a cell membrane. 13. Способ по п. 10, отличающийся тем, что на этапе (b) солюбилизация осуществляется путем обработки рекомбинантного белка с клеточной мембраной этапа (b) мочевиной. 13. The method according to p. 10, characterized in that in step (b), the solubilization is carried out by processing a recombinant protein with a cell membrane of the step (b) urea. 14. Способ по п. 10, отличающийся тем, что на этапе (c) отделение осуществляется центрифугированием, а полученная в результате надсадочная фракция содержит рекомбинантный белок. 14. The method according to p. 10, characterized in that at step (c) the separation is carried out by centrifugation, and the resulting supernatant fraction contains a recombinant protein. 15. Способ очистки выделенного рекомбинантного инсулина человека, включающий:
(a) подвергание выделенного рекомбинантного проинсулина человека сульфитолизу и отделение получаемого жидкого продукта;
(b) обработка жидкого продукта, полученного на этапе (а), на хроматографической никель-хелатирующей колонке с получением элюата;
(c) ренатурация элюата, полученного на этапе (b);
(d) превращение продукта, полученного на этапе (с), с использованием трипсина и карбоксипептидазы-В;
(e) хроматографическая обработка продукта, полученного на этапе (d), с получением очищенного выделенного рекомбинантного инсулина человека.15. The method of purification of the selected recombinant human insulin, including:
(a) subjecting the isolated recombinant human proinsulin to sulfitolysis and separating the resulting liquid product;
(b) processing the liquid product obtained in step (a) on a chromatographic nickel-chelating column to obtain an eluate;
(c) renaturation of the eluate obtained in step (b);
(d) converting the product obtained in step (c) using trypsin and carboxypeptidase-B;
(e) chromatographic treatment of the product obtained in step (d) to obtain purified isolated recombinant human insulin.
RU2000102364/13A 1997-07-02 1998-07-02 Vector for expression of heterologous protein, plasmid (variants) RU2222598C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/886,967 US6068993A (en) 1997-07-02 1997-07-02 Vector for expression of heterologous protein and methods for extracting recombinant protein and for purifying isolated recombinant insulin
US08/886,967 1997-07-02

Publications (2)

Publication Number Publication Date
RU2000102364A true RU2000102364A (en) 2002-03-27
RU2222598C2 RU2222598C2 (en) 2004-01-27

Family

ID=25390172

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2000102364/13A RU2222598C2 (en) 1997-07-02 1998-07-02 Vector for expression of heterologous protein, plasmid (variants)

Country Status (11)

Country Link
US (4) US6068993A (en)
EP (1) EP0996713B1 (en)
AT (1) ATE278776T1 (en)
BR (1) BR9810650B1 (en)
CA (2) CA2294760C (en)
DE (1) DE69826864T2 (en)
IL (2) IL133832A0 (en)
IN (1) IN187721B (en)
PL (1) PL194141B1 (en)
RU (1) RU2222598C2 (en)
WO (1) WO1999001548A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2497118C1 (en) * 2012-03-06 2013-10-27 Федеральное государственное бюджетное учреждение науки Институт биохимии и физиологии микроорганизмов им. Г.К. Скрябина Российской академии наук (ИБФМ РАН) FAST METHOD FOR TREATING INTESTINAL SMOOTH MUSCLE CELLS WITH Bacillus cereus HEMOLYSIN II

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7049286B2 (en) * 2001-08-30 2006-05-23 Diatos, S.A. Insulin conjugates and methods of use thereof
WO2004042003A2 (en) * 2002-11-01 2004-05-21 Promega Corporation Cell lysis compositions, methods of use, apparatus, and kit
SG146695A1 (en) 2003-09-26 2008-10-30 Japan Tobacco Inc Method of inhibiting remnant lipoprotein production
US7674621B2 (en) * 2004-05-21 2010-03-09 The United States Of America As Represented By The Department Of Health And Human Services Plasmids and phages for homologous recombination and methods of use
EP2626368B1 (en) 2004-07-19 2016-12-21 Biocon Limited Insulin-oligomer conjugates, formulations and uses thereof
US7935788B2 (en) * 2004-10-04 2011-05-03 National Research Council Of Canada Reverse cumate repressor mutant
EP1797186B1 (en) * 2004-10-04 2016-05-25 National Research Council Of Canada Expression system, components thereof and methods of use
WO2009032664A2 (en) * 2007-08-31 2009-03-12 The Regents Of The University Of Michigan Methods and compositions for increasing biological molecule stability
RU2453332C2 (en) 2007-10-16 2012-06-20 Байокон Лимитид Solid pharmaceutical composition (versions) and method for controlling glucose concentration therewith, method for preparing solid pharmaceutical compositions (versions), tablet (versions) and method for making amorphous particles
EP2552935B1 (en) * 2010-03-31 2020-05-27 AMSilk GmbH Separation of insoluble target proteins
CN102617703A (en) * 2012-04-14 2012-08-01 拜明(苏州)生物技术有限公司 Method for extracting exogenous expressive protein in fermentation bacteria efficiently without cracking
WO2015176067A2 (en) 2014-05-16 2015-11-19 The Regents Of The University Of California A long non-coding rna expressed in aggressive cancer
US10745457B2 (en) 2015-09-02 2020-08-18 Merck Sharp & Dohme Corp. Process for obtaining insulin with correctly formed disulfide bonds

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704362A (en) * 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
US4624926A (en) * 1981-01-02 1986-11-25 The Research Foundation Of State University Of New York Novel cloning vehicles for polypeptide expression in microbial hosts
NZ199391A (en) * 1981-01-02 1985-12-13 Genentech Inc Chimeric polypeptides comprising a proinsulin sequence,and preparation by recombinant dna technique;production of human insulin
US4503155A (en) * 1982-02-01 1985-03-05 Eli Lilly And Company Multifunctional, cloning vectors for use in Streptomyces, Bacillus, and E. coli
US4732859A (en) * 1982-09-03 1988-03-22 Eli Lilly And Company Method for conferring bacteriophage resistance to bacteria
US4599197A (en) * 1982-12-22 1986-07-08 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4578355A (en) * 1983-01-12 1986-03-25 The United States Of America As Represented By The Department Of Health And Human Services Plasmid cloning vector pAS1
US5256546A (en) * 1983-07-15 1993-10-26 Bio-Technology General Corp. Bacterial expression of porcine growth hormone
US4734368A (en) * 1984-03-23 1988-03-29 Huels Aktiengesellschaft Process for the bioconversion of fumarate to L-malate
US4870013A (en) * 1984-04-19 1989-09-26 Cetus Corporation SV40 early and RSV promoters useful in saccharomyces expression
US4581170A (en) * 1984-08-03 1986-04-08 E. R. Squibb & Sons, Inc. N-hydroxyl protecting groups and process and intermediates for the preparation of 3-acylamino-1-hydroxy-2-azetidinones
US5032510A (en) * 1984-09-26 1991-07-16 Eli Lilly And Company Method for expression and secretion in bacillus
US4766066A (en) * 1984-09-27 1988-08-23 Eli Lilly And Company Method of using bacteriophage lambda p1 promoter to produce a functional polypeptide in streptomyces
US4766224A (en) * 1985-08-19 1988-08-23 International Minerals & Chemical Corp. Purification and activation of proteins from insoluble inclusion bodies
US4766205A (en) * 1985-11-13 1988-08-23 Beatrice Companies, Inc. Method for isolation of recombinant polypeptides in biologically active forms
US4734362A (en) * 1986-02-03 1988-03-29 Cambridge Bioscience Corporation Process for purifying recombinant proteins, and products thereof
CA1304886C (en) * 1986-07-10 1992-07-07 Heinz Dobeli Metal chelate resins
CA1339955C (en) * 1986-10-14 1998-07-14 Richard Eugene Heiney Process for transforming a human insulin precursor to human insulin
SU1703693A1 (en) * 1987-02-09 1992-01-07 Всесоюзный научно-исследовательский институт генетики и селекции промышленных микроорганизмов Dna ppr-il 2-19 recombination plasmid which codes human interleucine-2 synthesis and structure escherichia coli strain, human interleucine-2 producent
CA1340522C (en) * 1987-03-10 1999-05-04 Heinz Dobeli Fusion proteins containing neighbouring histidines for improved purification
US5063158A (en) * 1987-11-09 1991-11-05 Eli Lilly And Company Recombinant DNA expression vector comprising both transcriptional and translational activating sequences
CA1340772C (en) * 1987-12-30 1999-09-28 Patricia Tekamp-Olson Expression and secretion of heterologous protiens in yeast employing truncated alpha-factor leader sequences
US5026639A (en) * 1988-01-14 1991-06-25 Nippon Mining Company, Limited Method to improve mRNA translation and use thereof for production of platelet factor-4
US5258287A (en) * 1988-03-22 1993-11-02 Genentech, Inc. DNA encoding and methods of production of insulin-like growth factor binding protein BP53
EP0337243A1 (en) * 1988-04-14 1989-10-18 F. Hoffmann-La Roche Ag Process for purifying recombinant human interleukin-2
US5262322A (en) * 1988-06-24 1993-11-16 Genentech, Inc. Host transformed with yeast gene and ubiquitin/polypeptide fusions
US4897465A (en) * 1988-10-12 1990-01-30 Abbott Laboratories Enrichment and concentration of proteins by ultrafiltration
US5115102A (en) * 1989-07-21 1992-05-19 Monsanto Company Variant proteins and polypeptides possessing enhanced affinity for immobilized-metal affinity matrices
WO1991011454A1 (en) * 1990-01-24 1991-08-08 The Upjohn Company Method of purifying recombinant polypeptides
US5223408A (en) * 1991-07-11 1993-06-29 Genentech, Inc. Method for making variant secreted proteins with altered properties
US5460954A (en) * 1992-04-01 1995-10-24 Cheil Foods & Chemicals, Inc. Production of human proinsulin using a novel vector system
US5648235A (en) * 1992-07-03 1997-07-15 Q.B.I. Enterprises Ltd. Method and means for the production of gene products, novel recombinant DNA vectors therefor and kits employing them
GB9224584D0 (en) * 1992-11-23 1993-01-13 Connaught Lab Use of outer membrane protein d15 and its peptides as vaccine against haempohilus influenzae diseases
US5648244A (en) * 1993-09-27 1997-07-15 President And Fellows Of Harvard College Production, purification, cleavage and use of fusion peptides
US6001604A (en) * 1993-12-29 1999-12-14 Bio-Technology General Corp. Refolding of proinsulins without addition of reducing agents
US5534428A (en) * 1994-09-06 1996-07-09 Life Technologies, Inc. Cloned Ssti/SacI restriction-modification system
US5850015A (en) * 1995-06-07 1998-12-15 Cornell Research Foundation, Inc. Hypersensitive response elicitor from Erwinia chrysanthemi
ZA979496B (en) * 1996-10-31 1999-04-23 Genentech Inc Assay using marked microbial host cell strains

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2497118C1 (en) * 2012-03-06 2013-10-27 Федеральное государственное бюджетное учреждение науки Институт биохимии и физиологии микроорганизмов им. Г.К. Скрябина Российской академии наук (ИБФМ РАН) FAST METHOD FOR TREATING INTESTINAL SMOOTH MUSCLE CELLS WITH Bacillus cereus HEMOLYSIN II

Similar Documents

Publication Publication Date Title
Hansson et al. Single–Step Recovery of a Secreted Recombinant Protein by Expanded Bed Adsorption
US5122457A (en) Expression systems utilizing bacteriophage t7 promoters, gene sequences, and t7 rna polymerase
JP2686090B2 (en) Novel fusion protein and purification method thereof
Jackson et al. Nucleotide sequence analysis of the structural genes for Shiga-like toxin I encoded by bacteriophage 933J from Escherichia coli
RU2000102364A (en) VECTOR FOR EXPRESSION OF A HETEROLOGICAL PROTEIN AND METHODS OF EXTRASION OF A RECOMBINANT PROTEIN AND CLEANING OF THE IDENTIFIED RECOMBINANT INSULIN
JP3054192B2 (en) Recombinant DNA method for the production of parathyroid hormone
US5643758A (en) Production and purification of a protein fused to a binding protein
JP2624470B2 (en) Production of streptavidin-like polypeptide
Brothers et al. Characterization of a surface antigen of Eimeria tenella sporozoites and synthesis from a cloned cDNA in Escherichia coli
EP0286239B1 (en) Production and purification of a protein fused to a binding protein
Zhang et al. Biological synthesis of monodisperse derivatives of poly (. alpha., L-glutamic acid): model rodlike polymers
SE460539B (en) HYBRID HUMANLEUCOCYT INTERFERONES, THE DNA SEQUENCE CODING FOR THEM, VECTOR CONTAINING THE DNA SEQUENCE, AND PHARMACEUTICAL COMPOSITION CONTAINING THE HYBRID HUMANLEUCOCYT INTERFERONES
CN100439391C (en) Process for producing hydrophobic polypeptides, proteins or peptides
CA2294760A1 (en) Vector for expression of heterologous protein and methods for extracting recombinant protein and for purifying isolated recombinant insulin
EP0510018A1 (en) Lipoprotein signal peptide fused to antigenic polypeptides
Slos et al. Recombinant cholera toxin B-subunit in Escherichia coli: high-level secretion, purification, and characterization
Lee et al. Purification of major fimbrial proteins of Porphyromonas gingivalis
JPS6361960B2 (en)
CA2002854A1 (en) Recombinant interleukin-2 hybrid proteins
CN108840934B (en) Recombinant sheep long-acting interferon tau, fusion protein for preparing long-acting interferon tau and preparation method of fusion protein
JPS61149089A (en) Polypeptide secretion development vector, microorganism transformed with same, and production of polypeptide with microorganism
EP0542761B1 (en) Eliminating internal initiation of soluble cd4 gene
JP2662044B2 (en) DNA sequence, expression vector and method for producing periplasm of polypeptide
JP2602067B2 (en) Flounder growth hormone, flounder growth hormone structural gene, recombinant plasmid for flounder growth hormone production, flounder pre-growth hormone, flounder pre-growth hormone structural gene, flounder pre-growth structural gene recombinant plasmid, flounder growth hormone, and method for producing flounder pre-growth hormone
CN114588256A (en) Development and application of porcine infectious pleuropneumonia subunit vaccine